Oncopeptides
Oncopeptides, a biotech developing targeted therapies for hard-to-treat cancers, has drug candidates based on its proprietary Peptide Drug Conjugate platform.
- Public company
- Stockholm, SESweden
Oncopeptides, a biotech developing targeted therapies for hard-to-treat cancers, has drug candidates based on its proprietary Peptide Drug Conjugate platform.
oncopeptides.comCrawled Nov 6, 2026
Oncopeptides’ melflufen clinical program seeks global regulatory approval and explores safe, effective use across indications.
Melflufen is the first Peptide Drug Conjugate (PDC) with an alkylating payload. The drug utilizes peptidases and esterases that are overexpressed in multiple
Multiple myeloma is an incurable cancer characterized by a proliferation of plasma cells in the bone marrow. The disease is associated with substantial
Pepaxti (melphalan flufenamide) is a Peptide Drug Conjugate (PDC) with an alkylating payload, developed for the treatment of adult patients with multiple
Oncopeptalks Archive - Oncopeptides
In the latest episode of Oncopeptalks, CEO Sofia Heigis and CFO Henrik Bergentoft comments on the Q1 report and other news presented during the week.
News Archive - Oncopeptides
Newsroom Archive - Oncopeptides
In an interview with Redeye, CEO Sofia Heigis discusses the significance of the data from the INSULA study in glioblastoma and how the SEK 100 million raised
Oncopeptides reports progress in developing treatment for glioblastoma, an aggressive brain cancer, based on interim analysis data.
Oncopeptides aims to attract, retain, and develop skilled professionals in the biotech industry.
Oncopeptides’ senior management team consists of the CEO, CFO, Chief Medical Officer, Chief Operating Officer, Director of IR & Communications and Head of
About Archive - Oncopeptides
Oncopeptides has a number of policy documents and manuals containing rules and recommendations providing guidance in the Company’s business operations and for
Oncopeptides integrates sustainability into its business operations and employee relationships.
Oncopeptides develops cancer therapies using proprietary technology, targeting diseases with significant unmet medical needs.
Oncopeptides AB (publ) outlines the terms and conditions governing use of its website.
Oncopeptides presents real-world clinical data on Pepaxti (melflufen) for treating relapsed, refractory multiple myeloma (RRMM) at ASH 2026. The findings stem from European patient outcomes in heavily pretreated cases. Two abstracts detailing these results have been accepted for the conference in New Orleans, December 12–15, 2026.
Nov 2026TradingViewNews article
Oncopeptides receives Norwegian regulatory approval to begin a window-of-opportunity clinical trial for glioblastoma. The study will explore the potential of its experimental therapy in treating this aggressive brain cancer before standard treatment begins. The approval marks a key step in advancing the company’s pipeline for oncology applications.
May 2026MarketScreenerNews article
Oncopeptides plans to submit a **Type II variation application** to the **European Medicines Agency (EMA)** to expand the approved use of its drug **Pepaxti** into **third-line multiple myeloma treatment**. The move follows an updated assessment of Europe’s evolving therapeutic and regulatory landscape for the drug.
May 2026manufacturingchemist.comNews article
Oncopeptides launches **Pepaxti® (melphalan flufenamide)** in Germany, marking its first European market. The biotech company submits an **AMNOG dossier** to Germany’s Federal Joint Committee (G-BA) to initiate commercialization. Pepaxti targets difficult-to-treat hematological diseases, expanding Oncopeptides’ therapeutic portfolio.
Oct 2022PR NewswireNews article